Every AI newsletter, investors ask questions on the investor interaction platform: what are the characteristics of the company’s products? Can AIDS be treated?
Jinghua Pharmaceutical Group Co.Ltd(002349) (002349.SZ) said on the investor interaction platform in February 18th that the company was not directly used for the treatment of AIDS drugs, and its intermediate products, the ritonavir series, could be used to synthesize anti HIV drugs.
